CADL
Candel Therapeutics, Inc.Company with tickers: CADL
CIK
1841387
CUSIP
137404109
Shares Outstanding
73,270,239
13F Activity (30d)
100 filings
98 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $16,284,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $9,840,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-16,284,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-8,861,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.14 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.14 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |